According to Actinium Pharmaceuticals's latest financial reports the company's current revenue (TTM) is $0.08 M. In 2022 the company made a revenue of $1.03 M a decrease over the years 2021 revenue that were of $1.14 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.08 M | -92.14% |
2022 | $1.03 M | -9.97% |
2021 | $1.14 M | |
2020 | N/A | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A | |
2012 | N/A | |
2011 | N/A | |
2010 | N/A | |
2009 | N/A | |
2008 | N/A | |
2007 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Genocea Biosciences
GNCA | $1.91 M | 2,259.26% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | $0.39 B | 492,932.10% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $2.41 B | 2,986,598.77% | ๐บ๐ธ USA |